Research team focuses on data mining and modeling for the diagnosis, treatment, and prognosis from the real-world clinical datasets of patients with hematologic disorders. In the past 4 years, 18 articles as first or corresponding author have been published in journals such as Nature Computational Science, Nature Communications, Blood, Leukemia, and American Journal of Hematology.
M.B.A., Washington University in St. Louis, St. Louis, MO, USA, 2011 – 2014
Ph.D., Molecular and Cellular Biology, Harvard University, Cambridge, MA, USA, 2004 – 2008
M.D, National Taiwan University, Taipei, Taiwan, China, 1996 – 2002
Chief Scientist, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 2020 –
Chief Scientist and Executive Vice Director, China Seed Life Science Center, Sinochem Group Co., Ltd, 2016 – 2020
Model Strategy Lead, The Climate Corporation, 2014 – 2016
Plant Health Pipeline Lead, Monsanto Company, 2013 – 2014
Germplasm Genomics Lead, Monsanto Company, 2012 – 2013
Statistical Genetics Lead, Monsanto Company, 2011 – 2012
PRINCIPAL HONORS, AWARDS:
2018 The Thousand Talents Program
2017 Wuhan “Optics Valley 3551” Talent Plan
2014 Monsanto Company Global Technology Above and Beyond Award
SELECTED PUBLICATIONS:
1. Liu X, Cao Y, Guo Y, Gong X, Feng Y, Wang Y, Wang M, Cui M, Guo W, Zhang L, Zhao N, Song X, Zheng X, Chen X, Shen Q, Zhang S, Song Z, Li L, Feng S, Han M, Zhu X, Jiang E, Chen J*. Dynamic forecasting of severe acute graft-versus-host disease after transplantation. Nat Comput Sci. 2022; 2, 153–159.
2. Cao Y, Gong X, Feng Y, Wang M, Hu Y, Liu H, Liu X, Qi S, Ji Y, Liu F, Zhu H, Guo W, Shen Q, Zhang R, Zhao N, Zhai W, Song X, Chen X, Geng L, Chen X, Zheng X, Ma Q, Tang B, Wei J, Huang Y, Ren Y, Song K, Yang D, Pang A, Yao W, He Y, Shang Y, Wan X, Zhang W, Zhang S, Sun G, Feng S, Zhu X, Han M, Song Z, Guo Y, Sun Z, Jiang E, Chen J*. The Composite Immune Risk Score predicts overall survival after allogeneic hematopoietic stem cell transplantation: A retrospective analysis of 1838 cases. Am J Hematol. 2023; 98(2):309-321.
3. Feng Y, Qi S, Hu Y, Yan W, Ji Y, Wang M, Gong X, Shen Q, Zhang W, Liu H, Zhang X, Chen M, Chen E, Zhai X, He Y, Yang D, Pang A, Han M, Gale RP, Sun Z, Jiang E, Chen J*. New criteria for estimating numbers of CD34-positive cells in a graft needed for posttransplant bone marrow recovery. Leukemia. 2024; 38(12):2735-2738.
4. Dong F, Zhang S, Zhu C, Yang Z, Wang L, Ma Y, Lu J, Li X, Wang X, Wang N, Zhang S, Xie M, Wang J, Zhang X, Zheng Y, Ma S, Ema H, Cheng H, Hao S, Suda T, Lan Y, Liu B, Zhu P, Chen J*, Cheng T. Heterogeneity of high-potency multilineage hematopoietic stem cells and identification of "Super" transplantability. Blood. 2025; 146(5):546-557.
5. Chen J*, et al.. Autonomous artificial intelligence prescribing a drug to prevent severe acute graft-versus-host disease in HLA-haploidentical transplants. Nat Commun. 2025; 16(1):8391.
6. Shen Q, Gale RP, Chen J*. Rethinking End Points in Modern Oncology Trials-Beyond the P Value. JAMA Oncol. 2025; 11(12):1553.